CLRB NASDAQ
Credit Risk of going bust: higher than 70% of companies Debt: 11.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 98%), Cellectar Biosciences, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $11.4M.
Distance to default 3.40 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $766K (short-term plus half of long-term), stock volatility 79.2%; Altman Z'' -19.22. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Florham Park, NJ 07932
US
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Loren Stefan | A-Award | 15,000 | $2.69 | 2026-07-08 |
| Loren Stefan | A-Award | 15,000 | $2.68 | 2026-07-08 |
| Kolean Chad J | A-Award | 92,000 | $3.14 | 2026-07-07 |
| DRISCOLL FREDERICK W | A-Award | 25,000 | $2.70 | 2026-07-07 |
| Chanan-Khan Asher | A-Award | 25,000 | $2.70 | 2026-07-07 |